ARVINDREM

Arvind Remedies Limited has informed the Exchange that it has been decided by the Board of Directors in their meeting that the financial year ending of 2014-15 will be June 30, 2015 and that the company will have the audited results for the 15 months. The company has requested the Registrar of Companies for extension of time to hold the Annual General Meeting by 3 months, i.e till December 2015.The Board will consider the audited financial results for the quarter ended March 31, 2015 and the quarter and year ended June 30, 2015 in one meeting, once the audit is completed. Company had sought ea

Arvind Remedies Limited has informed the Exchange that with reference to Company's earlier communications informing about strike in Unit No. 1 at Kakkalur, Thiruvallur, Tamil Nadu. Company have now inform the Exchange that since the conciliation efforts have failed, the matter will be continued at the Labour Court. In view of the above position, the strike by the workers stand discontinued.

Arvind Remedies Limited has informed the Exchange, vide letter dated June 11, 2014 regarding "MoU with Adesh University to launch new drugs - Press release".

Arvind Remedies Limited has informed the Exchange vide letter dated May 27, 2014 regarding "MoU with SRM University to launch new drugs for Diabetes and Coronary heart disease- Press release".

Arvind Remedies Limited has informed the Exchange that on February 10, 2014 the commercial operation of the new unit of the Company at Kakkalur, Tiruvellore, Tamil Nadu for few products has been started.

Arvind Remedies Limited has informed the Exchange vide letter dated October 18, 2013 regarding "MoU to manufacture and market drugs with four educational Institutions - Patents drugs for Alzheimer, Parkinson and depression".

Arvind Remedies Limited had informed the Exchange regarding the outcome of the Board Meeting held on May 15, 2013, including proposal for demerger of Irrungatukottal unit of the Company to Arvind Wellness Limited. The Company has now informed the Exchange that since the Irrungatukottai unit of the Company will have USFDA registration, to take care of the US strategy of business and to develop the US market for the products, the Company has set up a subsidiary Company in the name of Arvind Remedies LLC. in New Jersey, US.

Arvind Remedies Limited has informed the Exchange, vide letter dated October 19, 2012 that Mr. S. Sundara Raman, who was appointed as Chief Financial Officer of the Company resigned from the services.